PD-L1-IN-2

• UNSPSC Description:

  PD-L1-IN-2 is a potential tumor immunological agent by inhibiting PD-L1. PD-L1-IN-2 is a Naamidine J derivative and exerts antitumor effects in vivo by reducing PD-L1 expression and enhancing tumor-infiltrating T-cell immunity. PD-L1-IN-2 is used for colorectal cancer research[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-l1-in-2.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(CC2=C(CC3=CC(OC)=C(OC)C=C3)N(C)C(NC(C4=CC(NC(OC(C)(C)C)=O)=CC=C4)=O)=N2)C=C1

• Molecular Weight:

  586.68

• References & Citations:

  [1]Pan-Pan Fu, et al. Bioactivity-Driven Synthesis of the Marine Natural Product Naamidine J and Its Derivatives as Potential Tumor Immunological Agents by Inhibiting Programmed Death-Ligand 1. J Med Chem. 2023 Apr 27;66(8):5427-5438.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  2894733-91-4